CompletedNot Applicable

Liver Transplantation and Uveal Malignant Melanoma

Norway2 participantsStarted 2011-01

Plain-language summary

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Uveal malignant melanoma * Liver metastases * ECOG 0-1 Exclusion Criteria: * Extra hepatic disease * Previous other malignancy * Previous organ transplantation

What they're measuring

Over all survival

Timeframe: 1 year

Trial details

NCT IDNCT01311466

SponsorOslo University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-10

View on ClinicalTrials.gov More Uveal Malignant Melanoma trials